The Major Subunit of the Toxin-Coregulated Pilus TcpA Induces Mucosal and Systemic Immunoglobulin A Immune Responses in Patients with Cholera Caused by *Vibrio cholerae* O1 and O139

Muhammad Asaduzzaman,1 Edward T. Ryan,2 Manohar John,2 Long Hang,2 Ashraful I. Khan,1 A. S. G. Faruque,1 Ronald K. Taylor,3 Stephen B. Calderwood,2 and Firdausi Qadri1*

*International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh;1 Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts2; and Department of Microbiology and Immunology, Dartmouth Medical School, Hanover, New Hampshire3*

Received 16 February 2004/Returned for modification 21 March 2004/Accepted 10 April 2004

Diarrhea caused by *Vibrio cholerae* is known to give long-lasting protection against subsequent life-threatening illness. The serum vibriocidal antibody response has been well studied and has been shown to correlate with protection. However, this systemic antibody response may be a surrogate marker for mucosal immune responses to key colonization factors of this organism, such as the toxin-coregulated pilus (TCP) and other factors. Information regarding immune responses to TCP, particularly mucosal immune responses, is lacking, particularly for patients infected with the El Tor biotype of *V. cholerae* O1 or *V. cholerae* O139 since highly purified TcpA from these strains has not been available previously for use in immune assays. We studied the immune responses to El Tor TcpA in cholera patients in Bangladesh. Patients had substantial and significant increases in TcpA-specific antibody-secreting cells in the circulation on day 7 after the onset of illness, as well as similar mucosal responses as determined by an alternate technique, the assay for antibody in lymphocyte supernatant. Significant increases in antibodies to TcpA were also seen in sera and feces of patients on days 7 and 21 after the onset of infection. Overall, 93% of the patients showed a TcpA-specific response in at least one of the specimens compared with the results obtained on day 2 and with healthy controls. These results demonstrate that TcpA is immunogenic following natural *V. cholerae* infection and suggest that immune responses to this antigen should be evaluated for potential protection against subsequent life-threatening illness.

Diarrhea caused by *Vibrio cholerae* is known to give long-lasting protection against subsequent life-threatening illness (2, 3, 15). The serum vibriocidal antibody response has been well studied and has been shown to be correlated with protection (8, 16, 17, 18). However, this systemic antibody response may be a surrogate marker for mucosal immune responses to key colonization factors of this organism, such as the toxin-coregulated pilus (TCP). TCP is essential for *V. cholerae* colonization of the small intestine both in an infant mouse model of cholera (28) and during human infection (11). The gene encoding the major pilin subunit, TcpA, is located within a larger genetic element termed the *Vibrio* pathogenicity island or TCP/ACF element (7, 19). Although TcpA is expressed by both classical and El Tor biotypes of *V. cholerae* O1, as well as by *V. cholerae* O139, there is only 80% amino acid identity between the TcpA proteins of the two biotypes of *V. cholerae* O1 (12, 13, 28). TcpA of El Tor *V. cholerae* O1 and TcpA of *V. cholerae* O139 are identical (25).

In previous studies of the immune responses to TcpA in patients with *V. cholerae* infections the workers have examined patients infected with the classical biotype of *V. cholerae* O1 or have utilized classical TcpA to assess immune responses in patients infected with El Tor *V. cholerae* O1 (9). Recent studies in which the in vivo-induced antigen technology has been used have shown that TcpA is expressed during human infection with El Tor *V. cholerae* O1 and is immunogenic (10). Evidence for immunogenicity of El Tor *V. cholerae* O1 TcpA has also been obtained with convalescent-phase sera by utilizing partially purified El Tor TcpA and a monoclonal antibody-based sandwich assay (1).

Recently, recombinantly produced and purified El Tor TcpA has become available (5), and we utilized this reagent to carry out a detailed and comprehensive study of the mucosal and systemic immune responses to this colonization antigen in specimens obtained from patients with natural infections caused by El Tor *V. cholerae* O1 and *V. cholerae* O139 in Bangladesh.

(Preliminary results from this study were presented at the XII Annual Meeting of the International Centers for Tropical Disease Research, Bethesda, Md., May 2003.)

**MATERIALS AND METHODS**

**Study group.** Patients with acute watery diarrhea due to *V. cholerae* O1 or O139 were recruited to the study (Table 1). These patients included both males and females with cholera caused by the *V. cholerae* O1 Inaba (n = 30) and Ogawa (n = 30) serotypes, as well as patients with *V. cholerae* O139 infections. Healthy individuals in the same age range and with the same socioeconomic status but
with no history of diarrhea during the previous 3 months were included as controls.

**Microbiologic work-up.** Cholera was confirmed in patients with acute watery diarrhea by stool culture, and the organisms recovered were differentiated serologically as *V. cholerae* O1 Ogawa, O1 Inaba, or O139 (24). Stools of patients were also tested for the presence of other enteric pathogens (including *Salmonella*, *Shigella*, and *Campylobacter* spp.) by culture, for the presence of entero-toxigenic *Escherichia coli* by PCR, and for the presence of ova and parasites by direct microscopy, and the results were negative. Stools of healthy controls included in the study were screened for these pathogens and were negative.

**Sample collection and preparation.** After microbiological confirmation of cholera, venous blood and feces were collected from patients after they had been rehydrated. This occurred on the second day of hospitalization and was considered to be approximately 2 days after the onset of diarrhea (day 2). Serum and

### TABLE 1. Clinical features of study subjects

<table>
<thead>
<tr>
<th>Group</th>
<th>n</th>
<th>Age (yr) No. (%) of males</th>
<th>No. (%) of females</th>
<th>No. (%) infected with <em>V. cholerae</em> strain</th>
<th>No. (%) with blood group of</th>
<th>Duration of illness at presentation (h)</th>
<th>% with indicated degree of dehydration at presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>01 Ogawa 01 Inaba 0139</td>
<td>A  B  AB  O</td>
<td></td>
<td>Severe Mild</td>
</tr>
<tr>
<td>Patients</td>
<td>90</td>
<td>25 (18, 35) a</td>
<td>41 (45)</td>
<td>49 (55)</td>
<td>30 (33.3) 30 (33.3) 30 (33.3)</td>
<td>19 (21) 22 (25) 10 (11) 39 (43)</td>
<td>NA</td>
</tr>
<tr>
<td>Healthy controls</td>
<td>30</td>
<td>29 (24, 35) b</td>
<td>16 (53)</td>
<td>14 (47)</td>
<td>NA  NA  NA</td>
<td>7 (23) 10 (33) 2 (7) 11 (37)</td>
<td>NA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>No. (%) infected with <em>V. cholerae</em> strain</th>
<th>No. (%) with blood group of</th>
<th>Duration of illness at presentation (h)</th>
<th>% with indicated degree of dehydration at presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>01 Ogawa 01 Inaba 0139</td>
<td>A  B  AB  O</td>
<td></td>
<td>Severe Mild</td>
</tr>
<tr>
<td>30 (33.3) 30 (33.3) 30 (33.3)</td>
<td>19 (21) 22 (25) 10 (11) 39 (43)</td>
<td>7 (23) 10 (33) 2 (7) 11 (37)</td>
<td>NA</td>
</tr>
</tbody>
</table>

* Median (25 centile, 75 centile).
* NA, not applicable.

**FIG. 1.** TcpA-specific IgA responses in ALS assays for patients with cholera due to *V. cholerae* O1 Ogawa (O1/Og), O1 Inaba (O1/In), or O139. The data points indicate individual values, and the bars indicate geometric means. Asterisks indicate statistically significant differences between the day 2 responses and the day 7 responses (one asterisk, *P* < 0.01 to 0.001; two asterisks, *P* < 0.001). Statistically significant differences between the responses of healthy controls and the responses of patients during convalescence are indicated by dots (one dot, *P* < 0.01 to *P* < 0.001; two dots, *P* < 0.001). mAB, milliabsorbance units; HC, healthy controls.
fetal samples were also collected 5 and 19 days later, during convalescence (that is, 7 and 21 days after onset of the disease, respectively). For control patients, single blood and fecal samples were collected.

Peripheral blood mononuclear cells (PBMCs) were isolated from blood collected in heparinized vials (Vacutainer system; Becton Dickinson, Rutherford, N.J.) by gradient centrifugation with Ficoll-Isopaque (Pharmacia, Uppsala, Sweden). Plasma collected from the top of the Ficoll gradient was stored in aliquots at −20°C. Sera separated from blood collected in vials that did not contain any additive were divided into aliquots and stored at −20°C for antibody assays. Fecal extracts were prepared by mixing stools (1 g of feces in 4 ml of buffer) with phosphate-buffered saline containing EDTA (0.05 M), protease inhibitors, soybean trypsin inhibitor (100 µg/ml), and phenylmethylsulfonyl fluoride (10 mM) (23). One milliliter of fecal extract was equivalent to 0.25 g of stool. Fecal extracts were frozen in aliquots at −70°C.

For tests involving stored serum and fecal extracts, samples from all 90 patients were available for enzyme-linked immunosorbent assays (ELISA). For studies in which fresh PBMCs were used as the antibody in lymphocyte secretion (ALS) and antibody-secreting cell (ASC) assays, samples were available from only 50 cholera patients (15 patients with V. cholerae O1 Ogawa, 20 patients with V. cholerae O1 Inaba, and 15 patients with V. cholerae O139) and from only 24 cholera patients (10 patients with V. cholerae O1 Ogawa, 10 patients with V. cholerae O1 Inaba, and 4 patients with V. cholerae O139), respectively. Similarly, samples for all assays were not available from all control participants. The specific number of samples analyzed in each assay is indicated below.

Preparation of V. cholerae antigens used for immunologic assays. TcpA was overexpressed in E. coli BL21 with a histidine tag fused to the amino-terminal end and was prepared as described previously (5). Lipopolysaccharides (LPS) from V. cholerae O1 Ogawa (strain X25049) and O1 Inaba (strain 19479) were purified as described previously (30). The major pilin subunit of the mannose-sensitive hemagglutinin (MSHA) was purified from V. cholerae O1 and was prepared by a method described previously (14); MSHA was a gift from Ann-V. Svennerholm, Goteborg University, Goteborg, Sweden.

Detection of ASC in the circulation. The ASC assay is a well-established proxy for mucosal immune responses at the gut surface. Ficoll-separated PBMCs recovered from patients on days 2 and 7 after the onset of diarrhea were assayed for TcpA-specific ASC by the ELISPOT technique (6) by using modifications described previously (20, 22). Individual wells of nitrocellulose bottom 96-well plates (Millititer HA; Millicore Corp., Bedford, Mass.) were coated with 0.1 ml of TcpA (5 µg/ml) in 50 mM carbonate buffer (pH 9.6) and kept overnight at room temperature. Cells secreting antibodies of the immunoglobulin A (IgA), IgG, and IgM isotypes specific for bound TcpA were determined as described previously (20, 22). A positive ASC response was defined as more than 10 ASC/10⁷ PBMCs. TcpA-specific ASC responses were studied in 10 patients infected with V. cholerae O1 Ogawa, 10 patients infected with V. cholerae O1 Inaba, and 20 healthy controls. Since the incidence of infection caused by V. cholerae O139 was low during the course of the study, ASC responses to TcpA were determined in only four patients with V. cholerae O139 infections.

ALS. An optimized procedure for an alternate measure of the mucosal immune response to antigens, the ALS assay, has been described recently (4, 23). Since this technique can be used with samples that were previously collected and frozen, we used the ALS assay to compare TcpA-specific responses in patients with V. cholerae O1 and O139 infections, including patients seen in a previous study of O139 infection (23). For the ALS assay, isolated PBMCs separated from patient samples collected on days 2 and 7 were incubated in 24-well tissue culture plates at a concentration of 1 × 10⁶cells/ml in RPMI medium (with 10% fetal bovine serum, 1% glutamine, 1% sodium pyruvate, 1% penicillin-streptomycin) at 37°C in 5% CO₂ for 48 h by using sterile techniques. After incubation, the plates were centrifuged at 1,200 × g for 10 min, and the supernatants were collected. A protease inhibitor cocktail containing aprotonin (0.15 µM), leupeptin (10 µM), soybean azidase (15 µM), and 4-(aminoethyl)benzenesulfonyl fluoride (0.2 µM) was added to each supernatant (10 µl/m of supernatant), and the samples were frozen immediately in aliquots at −70°C until they were assayed. The ALS assay was used to determine TcpA-specific IgA antibody responses in an ELISA as described below; the anti-TcpA response was measured in 15 patients with a V. cholerae O1 Ogawa infection, 20 patients with a V. cholerae O1 Inaba infection, and 15 patients with a V. cholerae O139 infection. Twenty healthy volunteers were also tested by the ALS assay.

Detection of TcpA-specific antibodies in sera, feces, and lymphocyte supernatants by ELISA. Serum samples collected from patients at the acute stage of infection (day 2) and at the convalescent stage of infection (day 7 and day 21 after onset) were tested against TcpA (coating concentration in 50 mM carbonate buffer [pH 9.6], 1 µg/ml) by using previously described procedures (20). The ALS specimens were assayed undiluted, while serum samples were tested at a 1:200 dilution. The optical densities were measured kinetically at 450 nm for 5 min, and the results were expressed as the change in milliabsorbance units per minute (26). Fecal extracts were tested for antibody to TcpA by an ELISA, and the results were expressed as the change in milliabsorbance units per microgram of total IgA in the extract (26). A twofold or greater increase in the ELISA results between day 2 and either day 7 or 21 was considered a positive response.

Detection of LPS- and MSHA-specific IgA responses in sera, fecal extracts, and lymphocyte supernatants from V. cholerae O1 patients. Immune responses in sera, fecal extracts, and lymphocyte supernatants obtained from patients infected with V. cholerae O1 Inaba (n = 20) and V. cholerae O1 Ogawa (n = 15) to homologous LPS, as well as MSHA, were also studied by utilizing procedures described previously (20–23). ELISA plates were coated with LPS at a concentration of 2.5 µg/ml with or without MSHA at a concentration of 1.0 µg/ml.

Statistical analyses. The Wilcoxon signed rank test, the rank sum test, and the Mann-Whitney U test were used where applicable for statistical analysis. Data were expressed as medians and 25 and 75 centiles or as geometric means. A two-sided P value of ≤0.05 was considered significant. Analyses were carried out by using the SigmaStat statistical software (Jandel Scientific, San Rafael, Calif.).

RESULTS

Clinical features of the study subjects. Patients with cholera most commonly presented with a short history of diarrhea
(symptoms for 24 h or less), and 88% had severe diarrhea as determined by World Health Organization criteria (Table 1). The median ages, gender distributions, and ABO blood group distributions were similar for patients and controls.

TcpA-specific ASC responses in blood. Study subjects had very low TcpA-specific ASC responses on day 2 (Table 2). The TcpA-specific ASC responses of the IgA isotype were significantly elevated by day 7 in all three groups of study subjects (Table 2). Seven of 10 patients with a *V. cholerae* O1 Ogawa infection showed a positive IgA ASC response at day 7 (*P* < 0.009), as did 7 of 10 subjects infected with *V. cholerae* O1 Inaba (*P* < 0.016). All four patients infected with *V. cholerae* O139 studied showed an increase in TcpA-specific ASC responses on day 7. ASC responses were also seen in the IgG and IgM isotypes, and the frequencies and magnitudes of the responses were similar. The levels of ASC responses to TcpA were negligible in all 20 healthy controls studied and similar to those seen on day 2 in the study subjects (results not shown).

TcpA-specific IgA responses in the antibody in the lymphocyte supernatant assay (ALS assay). TcpA-specific IgA responses were also seen in the ALS assay in patients on day 7 of illness compared with the responses in patients on day 2 or in healthy controls (Fig. 1). Twelve of 15 patients with a *V. cholerae* O1 Ogawa infection, 12 of 20 patients with a *V. cholerae* O1 Inaba infection, and 10 of 15 patients with a *V. cholerae* O139 infection showed increases in the ALS response at day 7 compared to the response at day 2. The TcpA-specific levels in the ALS assay were low on day 2 and comparable to those seen in healthy controls (the difference was not significant).

TcpA-specific antibody responses in sera of patients with cholera. All three groups of patients infected with *V. cholerae* showed significant increases in serum IgA antibody responses to TcpA on days 7 and 21 compared to the responses on day 2 (Table 3). Sixty-three percent of the patients with a *V. cholerae* O1 Ogawa infection showed a significant increase in the level of serum IgA antibody to TcpA at day 7, compared with 60% of the patients infected with *V. cholerae* O1 Inaba and 73% of the patients infected with *V. cholerae* O139. The serum IgA antibody levels in 30 healthy controls were low and comparable to those seen at day 2 in patients (median, 3.83 milliabsorbance units/min; range, 2.33 to 5.33 milliabsorbance units/min).

TcpA-specific IgA responses in fecal extracts. Patients with a *V. cholerae* infection showed significant increases in TcpA-specific antibody in fecal extracts on days 7 and 21 compared with the levels on day 2 (Table 3). Significant increases in the TcpA-specific antibody level in fecal extracts were found in 83% of the patients infected with *V. cholerae* O1 Ogawa, compared with 80% of the patients infected with *V. cholerae* O1

<table>
<thead>
<tr>
<th>No. of positive ASC/10^7 PBMCs</th>
<th><em>P</em> value compared to day 2</th>
<th>Response rate compared to day 2 (%)</th>
<th>No. of positive ASC/10^7 PBMCs</th>
<th><em>P</em> value compared to day 2</th>
<th>Response rate compared to day 2 (%)</th>
<th>No. of positive ASC/10^7 PBMCs</th>
<th><em>P</em> value compared to day 2</th>
<th>Response rate compared to day 2 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.0 (0.01, 210)</td>
<td>0.025</td>
<td>60</td>
<td>0.01 (0.01, 0.01)</td>
<td>NA</td>
<td>NA</td>
<td>70.6 (10, 120)</td>
<td>0.03</td>
<td>80</td>
</tr>
<tr>
<td>15 (0.01, 50)</td>
<td>0.031</td>
<td>60</td>
<td>0.01 (0.01, 0.01)</td>
<td>NA</td>
<td>NA</td>
<td>125 (0.01, 230)</td>
<td>0.016</td>
<td>70</td>
</tr>
<tr>
<td>90 (75,115)</td>
<td>0.029</td>
<td>100</td>
<td>0.01 (0.01, 0.01)</td>
<td>NA</td>
<td>NA</td>
<td>90 (50, 190)</td>
<td>0.029</td>
<td>100</td>
</tr>
</tbody>
</table>
Inaba and 77% of the patients infected with *V. cholerae* O139. Low levels of fecal antibodies specific for TcpA were found in healthy controls, and the levels were comparable to those seen on day 2 in infected patients (median, 0.10 milliabsorbance unit/min/µg of total IgA; range, 0.01 to 2 milliabsorbance units/min/µg of total IgA).

**Immunoblot assays for immune responses to TcpA with serum and fecal extracts.** We utilized Western immunoblotting to detect specific antibody responses to the 20.5-kDa purified TcpA protein separated by polyacrylamide gel electrophoresis. The convalescent-phase sera of *V. cholerae* patients collected on day 7 or 21 following infection specifically recognized the TcpA protein when Western blotting was used (see representative patient samples in Fig. 2A). Fecal extracts from these patients also specifically detected TcpA protein when Western blotting was used (see representative patient samples in Fig. 2B). Over 80% of the patients with a *V. cholerae* O1 or O139 infection had antibody in the serum and/or fecal extracts that recognized TcpA by day 7 of infection, whereas none of these patients had antibody to this protein on day 2. In 10 healthy controls, neither sera nor fecal extracts recognized TcpA when immunoblotting was used.

**Comparison of immune responses to TcpA with immune responses to LPS and MSHA.** We compared immune responses to TcpA, LPS, and MSHA in patients infected with *V. cholerae* (Table 4). The responder frequency rates for TcpA and MSHA in all three assays were similar, whereas the responder frequency rates for LPS were slightly higher in ALS and serum assays. Overall, 93% of the patients with a *V. cholerae* O1 infection showed an IgA immune response to TcpA in one or more of the assays (ALS, serum antibody, and antibody in fecal extract).

**DISCUSSION**

The results obtained here demonstrate that the 20.5-kDa subunit of TCP (TcpA) is immunogenic in patients infected with *V. cholerae* O1 El Tor and *V. cholerae* O139 in Bangladesh. Previous studies have shown that individuals convalescing from cholera have strong immune responses to the B subunit of cholera toxin and to the LPS of the infecting strain (24). Patients with cholera also have immune responses, albeit weaker, to another type IV pilus of *V. cholerae*, the 17.4-kDa pilus subunit of the MSHA (22, 23). The immune response to the B subunit of cholera toxin, to LPS, and to MSHA, however, have not been shown to correlate with protection against subsequent infection with *V. cholerae*. The vibriocidal antibody response has been shown previously to correlate with protection (8, 16, 17, 18). However, this serum complement-fixing antibody is unlikely to be active at the mucosal surface, where complement is lacking. Therefore, the vibriocidal antibody response may be a surrogate marker of a protective mucosal immune response to another antigen.

Previous studies in which patients with cholera were examined for immune responses to TcpA either have been performed with North American volunteers challenged with the classical biotype of *V. cholerae* O1 or have utilized classical TcpA for immune assays with patients infected with El Tor *V. cholerae* O1 (9); these studies have shown that there are low rates of seroconversion. However, given that classical and El Tor TcpA exhibit only 80% amino acid identity (12, 13, 28), these previous studies may have underestimated the immune responses to TcpA in patients infected with El Tor *V. cholerae* O1. The recent availability of recombinantly produced and purified El Tor TcpA (5) has provided a more suitable reagent for assessing these immune responses. The results reported here demonstrate that both systemic and mucosal immune responses to TcpA occur in patients infected with El Tor *V. cholerae* O1, as well as in patients infected with *V. cholerae* O139, and that these responses are comparable in magnitude and frequency to those seen with LPS and MSHA. This dispels previous speculation that TcpA may not be sufficiently antigenic to engender an immune response or that repeated exposure may be needed for an adequate response. The rate of
immune responses to TcpA demonstrated here, in fact, is similar to that seen with other *V. cholerae* antigens studied. It is not yet known, however, whether an immune response to TcpA is protective.

In addition to the ASC assay, we also assessed mucosal immune responses to TcpA with the ALS assay. We have previously shown that the mucosal immune responses to LPS,CtxB, and MSHA assessed by the ALS assay are comparable to the responses seen with the ASC assay. One of the important features of the ALS assay is that supernatants recovered from circulating lymphocytes obtained on day 7 of infection can be stored frozen on a long-term basis and then assayed at a future time. We utilized this property specifically to assess mucosal immune responses to TcpA in patients infected with *V. cholerae* O139, using samples from a previous study. The results obtained were comparable to those obtained in the ALS and ASC assays for the small number of patients studied acutely. This suggests that supernatants of lymphocytes collected during an outbreak can be recovered and frozen for study of immune responses at a later time, particularly when mucosal immune responses to a newly isolated antigen need to be measured. Since positive results in the ASC or ALS assay differentiate recent infection from past exposure to the pathogen in question, this approach allows measurement of an acute immune response at a later time.

We have an ongoing study in Bangladesh of patients hospitalized with cholera and their household contacts (27). Some of the household contacts develop symptomatic cholera, some are asymptomatically colonized, and some are not infected. Frozen supernatants from circulating lymphocytes obtained from exposed household contacts in the various categories after exposure to *V. cholerae* are currently being analyzed by the ALS assay to see if a robust mucosal immune response to TcpA after exposure might be responsible for mediating protective immunity.

In conclusion, our study showed that patients infected with El Tor *V. cholerae* O1 or O139 in Bangladesh mount substantial mucosal and systemic immune responses to the colonization antigen TcpA and that these responses are comparable in magnitude and frequency to the responses to other *V. cholerae* antigens tested to date. We are currently examining whether immune responses to this key colonization factor may be involved in protective immunity, both in household contacts exposed to *V. cholerae* and in individuals vaccinated with a live, oral, attenuated cholera vaccine.

TABLE 4. Comparison of the TcpA-specific IgA antibody responses to responses to other antigens in patients infected with *V. cholerae* O1

<table>
<thead>
<tr>
<th>Immune assay</th>
<th>Responder frequency (%)</th>
<th>Day 2</th>
<th>Day 7</th>
<th>Cumulative response rate compared to day 2 (%)*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>TcpA</td>
<td>MSHA</td>
<td>LPS</td>
<td></td>
</tr>
<tr>
<td>Serum</td>
<td>62</td>
<td>69</td>
<td>77</td>
<td>NA</td>
</tr>
<tr>
<td>Fecal extract</td>
<td>82</td>
<td>69</td>
<td>77</td>
<td>NA</td>
</tr>
</tbody>
</table>

ACKNOWLEDGMENTS

This work was supported by grants from the National Institute of Allergy and Infectious Diseases (grant U01 AI58935 to S.B.C. and grant RO1 AI40725 to E.T.R.), by a training grant from the Fogarty International Center (grant D43 TW05372 to S.B.C.), and by the International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR,B). The ICDDR,B is supported by countries and agencies which share its concern for the health problems of developing countries.

We are grateful to Ann-Mari Svennerholm, Goteborg University, Goteborg, Sweden, for supplying MSHA.

REFERENCES


